Bausch Health Companies Inc. (BHC)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 3
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore ≥ 3 before any bullish entry. Price, liquidity, and event-window checks are acceptable, but the hard fundamental override blocks a long setup.
Company overview
Bausch Health Companies Inc. develops, manufactures, and commercializes pharmaceutical products, medical devices, and over-the-counter remedies. Its main therapeutic areas include ophthalmology, digestive health, and dermatology. The company operates through divisions such as Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
Fundamental
weakBausch Health's high leverage and negative equity overshadow its cash generation, resulting in a fundamental score of 2/5.
Operations are sizable and cash-generative (FY2025 free cash flow about $1.0B), and revenue has grown at a mid-single-digit pace over five years. But leverage is very high (net debt/EBITDA ~9.91x TTM) with negative shareholder equity and an Altman Z-Score around 0.01. The latest 10-Q shows a $1.426B Salix goodwill impairment after failed Phase 3 trials, swinging GAAP results to a large loss despite management reporting adequate liquidity and covenant compliance. Overall: potentially undervalued on cash flow, but elevated balance-sheet risk drives a 2/5 fundamental score.
Sentiment
fairMedia tone is neutral with some improvement, but no significant catalysts are present.
Short-term media tone around BHC is broadly neutral but modestly better than the prior 30–90d baseline, led by an announced 2026-06-25 debt-refinancing/debt-profile update and incremental product-news flow. There are no forward-dated catalysts surfaced for the next month and Reddit/retail sentiment is indeterminate (ticker collision + rate limit); legal/regulatory scans show no active investigations or cases in the last 90 days.
Technical
fairThe stock shows a high-volume rebound above short-term averages but remains below the 200-day average.
BHC has improved short-term technically: price is above SMA20 5.08, SMA50 5.37, EMA9 5.07, and EMA21 5.11, RSI14 recovered to 58.2, and MACD (-0.08 vs -0.12 signal) turned up with a positive histogram. The chart is not fully repaired, though, because price is still below SMA200 6.06 and below the latest daily VWAP 5.53, while ADX14 at 49.74 says the broader trend regime is still very strong. For a 1–15 day window that reads as an improving bounce, not a clean all-clear uptrend.
You’re looking at 2026-06-26 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.